Trial Profile
A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Oportuzumab monatox (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions
- 06 Jun 2023 Status changed from suspended to completed.
- 18 Jul 2022 Status changed from recruiting to suspended, According to Sesen Bio media release.
- 18 Jul 2022 According to Sesen Bio media release, the company plans to voluntarily pause further development in the US of its lead asset, Vicineum.